UP!
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2022 | 2022-11-01 | Future report Set alerts | |
| Q2 2022 | 2022-08-04 | -0.23 | -0.23 |
| Q1 2022 | 2022-05-04 | -1.02 | -1.02 |
| Q4 2021 | 2022-02-24 | -0.36 | -0.36 |
| Q3 2021 | 2021-11-03 | -0.95 | -0.95 |
| Q2 2021 | 2021-08-05 | -0.86 | -0.86 |
| Q1 2021 | 2021-05-06 | -0.66 | -0.66 |
| Q4 2020 | 2021-02-25 | -0.62 | -0.62 |
| Q3 2020 | 2020-11-04 | 0.00 | 0.00 |
| Q2 2020 | 2020-08-06 | -0.68 | -0.68 |
| 2016-06-21 | Reiterated Rating | FBR & Co. | Buy | $24.00 |
| 2016-06-21 | Reiterated Rating | FBR & Co | Buy | $24.00 |
| 2016-05-25 | Reiterated Rating | Piper Jaffray | Overweight | $24.00 |
| 2016-05-25 | Reiterated Rating | Piper Jaffray Cos. | Overweight | $24.00 |
| 2016-05-02 | Reiterated Rating | FBR & Co. | Buy | |
| 2016-04-30 | Reiterated Rating | Roth Capital | Buy | |
| 2016-03-09 | Lower Price Target | JPMorgan Chase & Co. | Market Outperform | $16.00 to $14.00 |
| 2016-03-09 | Lower Price Target | JMP Securities | Market Outperform | $16.00 to $14.00 |
| 2016-02-23 | Reiterated Rating | Roth Capital | Buy | $22.00 |
| 2016-02-17 | Reiterated Rating | Cowen and Company | Buy | $16.00 |
| 2016-01-20 | Reiterated Rating | Roth Capital | Buy | $22.00 |
| 2016-01-05 | Reiterated Rating | Piper Jaffray | Overweight | $24.00 |
| 2015-12-16 | Reiterated Rating | Piper Jaffray | Buy | $17.00 to $24.00 |
| 2015-11-10 | Boost Price Target | FBR & Co. | Outperform | $14.00 to $24.00 |
| 2015-11-09 | Boost Price Target | Roth Capital | Buy | $18.00 to $22.00 |
| 2015-10-23 | Reiterated Rating | Roth Capital | Buy | $18.00 |
| 2015-09-15 | Reiterated Rating | FBR & Co. | Outperform | $14.00 |
| 2015-07-31 | Reiterated Rating | Roth Capital | Buy | $18.00 |
| 2015-07-24 | Reiterated Rating | MLV & Co. | Buy | $9.00 to $14.00 |
| 2015-07-15 | Reiterated Rating | Roth Capital | Buy | $18.00 |
| 2015-07-15 | Initiated Coverage | Cowen and Company | Outperform | $9.00 |
| 2015-05-01 | Reiterated Rating | MLV & Co. | Buy | $9.00 |
| 2015-02-13 | Upgrade | Piper Jaffray | Neutral to Overweight | $13.00 |
| 2015-01-26 | Set Price Target | Roth Capital | Buy | $18.00 |
| 2014-12-31 | Boost Price Target | Roth Capital | Buy | $13.00 to $18.00 |
| 2014-11-04 | Upgrade | MLV & Co | Hold to Buy | $9 |
| 2014-11-04 | Upgrade | MLV & Co. | Hold to Buy | $5.00 to $9.00 |
| 2014-10-20 | Reiterated Rating | Roth Capital | Buy | |
| 2014-07-10 | Reiterated Rating | Roth Capital | Buy | |
| 2014-05-19 | Reiterated Rating | Leerink Swann | Outperform | $20.00 to $8.00 |
| 2014-05-08 | Reiterated Rating | Canaccord Genuity | Buy | $9.00 to $8.00 |
| 2014-04-28 | Reiterated Rating | Canaccord Genuity | Buy | $22.00 to $9.00 |
| 2014-04-28 | Lower Price Target | Needham & Company LLC | Buy | $25.00 to $15.00 |
| 2014-04-25 | Downgrade | MLV & Co. | Buy to Hold | $26.00 to $5.00 |
| 2014-04-25 | Downgrade | Piper Jaffray | Overweight to Neutral | $18.00 to $7.00 |
| 2014-03-05 | Initiated Coverage | Roth Capital | Buy | $25.00 |
| 2014-02-21 | Lower Price Target | Piper Jaffray | $24.00 to $18.00 | |
| 2013-10-11 | Reiterated Rating | Needham & Company LLC | Buy | |
| 2013-06-26 | Reiterated | MLV & Co | Buy | $24 to $26 |
| 2012-07-02 | Initiated | Needham | Buy | $2.50 |
| 2009-10-29 | Downgrade | Needham | Buy to Hold | |
| 2009-09-21 | Reiterated | Wedbush Morgan | Outperform | $4 to $18 |
| 2008-03-19 | Reiterated | Cantor Fitzgerald | Buy | $19 to $16 |
| 2007-07-19 | Initiated | Credit Suisse | Outperform | $11 |
| 2007-02-01 | Reiterated | Cantor Fitzgerald | Buy | $8 to $19 |
| 2007-01-03 | Reiterated | Rodman & Renshaw | Mkt Outperform | $10 to $12 |
| 2007-01-03 | Reiterated | RBC Capital Mkts | Sector Perform | $8 to $10 |
| 2016-06-21 | Reiterated Rating | FBR & Co. | Buy | $24.00 |
| 2016-06-21 | Reiterated Rating | FBR & Co | Buy | $24.00 |
| 2016-05-25 | Reiterated Rating | Piper Jaffray | Overweight | $24.00 |
| 2016-05-25 | Reiterated Rating | Piper Jaffray Cos. | Overweight | $24.00 |
| 2016-05-02 | Reiterated Rating | FBR & Co. | Buy |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In CYTK 218 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| BlackRock Inc. | 14.57M |
| FMR LLC | 12.89M |
| Vanguard Group, Inc | 9.99M |
| WELLINGTON MANAGEMENT CO LLP | 4.84M |
| STATE STREET CORP | 4.26M |
| LORD, ABBETT & CO. LLC | 3.76M |
| RTW INVESTMENTS, LLC | 2.57M |
| Partner Fund Management, L.P. | 2.47M |
| Boxer Capital, LLC | 2.10M |
| BlackRock Fund Advisors | 1.63M |
| FARALLON CAPITAL MANAGEMENT LLC | 1.62M |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 1.61M |
| GEODE CAPITAL MANAGEMENT, LLC | 1.59M |
| Invesco Ltd. | 1.41M |
| MORGAN STANLEY | 1.41M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| SCHMERTZLER MICHAEL | 11.86% (4340923) | CYTK / PTCT / |
| Eastern Capital LTD | 7.88% (2883845) | ASTM / CYCC / CYTK / IBIO / PPHM / |
| DOW STEPHEN M | 3.88% (1421052) | ALDR / CTXS / CYTK / |
| Blum Robert I President & CEO | 0.49% (180022) | CYTK / |
| Malik Fady Ibraham SVP Research & Early Dev | 0.27% (98072) | CYTK / |
| Cragg David SVP Human Resources | 0.23% (85865) | CYTK / |
| WOLFF ANDREW A SVP Clinical R&D, CMO | 0.13% (47255) | CYTK / |
| Morgan Bradley Paul SVP Drug Discovery & Early Dev | 0.13% (46441) | CYTK / |
| Schnieders Elisabeth Sr. VP, Business Development | 0.12% (43919) | CYTK / |
| BARBARI SHARON SURREY EVP, Finance & CFO | 0.11% (40323) | CYTK / OCLS / |
| GAGE L PATRICK | 0.10% (35000) | CYTK / PDLI / TTPH / |
| McDowell Caryn Gordon GC & Chief Compliance Officer | 0.09% (32548) | CYTK / RVNC / |
| CHARPENTIER BONNIE SVP Regulatory & Compliance | 0.08% (29004) | CYTK / |
| RODDY PETER S SVP Finance & CAO | 0.06% (21520) | CYTK / PTIE / VRML / |
| Jaw Ching SVP Finance & CFO | 0.05% (20000) | CYTK / |
UM